Log on / register
BioMed Central home | Journals A-Z | Feedback | Support | My details
Open AccessHighly AccessResearch

Does harm reduction programming make a difference in the lives of highly marginalized, at-risk drug users?

Susan J Rogers1 email and Terry Ruefli2 email

1Academy for Educational Development (AED), 100 Fifth Ave., New York, New York 10011, USA

2903 Dawson St., Bronx, New York 10459, USA

author email corresponding author email

Harm Reduction Journal 2004, 1:7doi:10.1186/1477-7517-1-7

Published: 1 June 2004

Abstract

Harm reduction is a controversial model for treating drug users, with little formal research available on its operation and effectiveness. In order to advance the field, we first conducted participatory research of harm reduction with 120 clients using nominal-group technique to develop culturally relevant outcomes to measure progress. Second, we conducted focus group interviews with a different group of clients to help validate the outcomes. Third, we used the outcomes in an evaluation of the largest harm reduction program in New York City, which involved a representative sample of 261 and entailed baseline, post, and six follow-up assessments. The participatory research resulted in outcomes of 10 life areas important to drug users. Evaluation results showed that program participants made positive improvements across most outcomes, with the most substantial progress made in how clients dealt with drug-use problems. Along with their participation in the program, progress in some outcomes was also associated with clients' type of drug use (i.e., stable vs. chaotic), where more stable drug use was associated with better ways of making an income and types of housing. Surprisingly, progress was not associated with the kinds or numbers of services received or the length of time in the program. This was attributed to the service delivery model of harm reduction, in which clients are less inclined to associate their success with a single staff person or with a single service or intervention received than with the program as a whole.


© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.